Advances in the management of cutaneous toxicities of targeted therapies

Abstract

Contrary to what might have been expected, the effects of targeted therapies are not limited to the cancer cells and are unfortunately associated with many and numerous adverse events. Dermatologic manifestations are among the most frequently observed, and, when severe and/or protracted, they inevitably impact the quality of life of patients. Management of these various side effects is empirical and mostly based on expert advice and consensus. We will review the skin side effects of EGFR, VEGFR, KIT, platelet-derived growth factor receptor (PDGFR), and BCR-ABL inhibitors, as well as mTOR inhibitors.